Abvc Biopharma (ABVC) Non-Current Assets (2010 - 2026)

Abvc Biopharma (ABVC) has reported Non-Current Assets for 15 consecutive years, with $19.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets rose 287.56% year-over-year to $19.0 million; the trailing twelve-month figure through Jun 2026 stood at $60.9 million (up 117.48% YoY), and the FY2025 full-year result was $1.1 million, up 3.8% from the prior year.
• Non-Current Assets steadied at $19.0 million in Q2 2026 per ABVC's latest filing, from $19.1 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $19.1 million in Q1 2026 and bottomed at $644654.0 in Q2 2023.
• Historically, Non-Current Assets has averaged $5.3 million across 5 years, with a median of $1.1 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Non-Current Assets sank 80.35% in 2023, then soared 1957.54% in 2025.
• Over 5 years, Non-Current Assets stood at $739472.0 in 2022, then decreased by 7.2% to $686206.0 in 2023, then surged by 57.89% to $1.1 million in 2024, then advanced by 3.8% to $1.1 million in 2025, then surged by 1588.47% to $19.0 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $19.0 million, $19.1 million, and $1.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.